Vanderbilt Vaccine Center Archives
Symposium on modeling immunity set for April 27
Mar. 30, 2017—The 2017 Vanderbilt Symposium on Modeling Immunity will be held from 1 to 4:30 p.m. Thursday, April 27, in room 1220 MRB III.
Crowe’s pediatric immune response research lauded
Feb. 23, 2017—James Crowe Jr., M.D., director of the Vanderbilt Vaccine Center, is the 2017-2018 recipient of the Samuel Rosenthal Prize for Excellence in Academic Pediatrics.
Team isolates new antibodies that may aid RSV vaccine design
Feb. 9, 2017—Researchers at Vanderbilt University Medical Center (VUMC) have taken another step toward developing a vaccine against respiratory syncytial virus (RSV), the major cause of life-threatening pneumonia in infants worldwide.
Early study finds antibody that ‘neutralizes’ Zika virus
Nov. 7, 2016—Researchers at Vanderbilt University Medical Center and Washington University School of Medicine in St. Louis have isolated a human monoclonal antibody that in a mouse model “markedly reduced” infection by the Zika virus.
Preparing for a return of pox
Oct. 20, 2016—To prepare for the potential of a smallpox return, Vanderbilt researchers are isolating and studying naturally occurring antibodies from the blood of previously infected or immunized people.
Research sheds light on how RSV wards off potential vaccines
Oct. 20, 2016—Respiratory syncytial virus (RSV) is the major cause of life-threatening viral pneumonia in infants worldwide, yet despite repeated efforts, scientists have been unable to develop an effective vaccine against it.
Targeting norovirus “noxiousness”
Sep. 28, 2016—New discoveries will guide efforts to develop vaccines or antiviral agents for norovirus, the most common cause of infectious diarrhea.
Investigators create ‘Trojan Horse’ to fight Ebola
Sep. 8, 2016—A multi-center research team including scientists from the Vanderbilt Vaccine Center has come up with a clever “Trojan Horse” strategy for thwarting the highly lethal Ebola virus.
Research team takes aim at Ebola virus ‘decoy protein’
Aug. 11, 2016—Using an antibody generated at Vanderbilt University Medical Center that neutralizes the Ebola virus, researchers at the Scripps Research Institute in La Jolla, California, have determined the structure of a “decoy” protein that may enable the virus to evade detection by the immune system.
Vanderbilt and Human Vaccines Project launch initial studies to decode the human immune system
Jun. 21, 2016—Researchers at Vanderbilt University Medical Center this month began recruiting volunteers to participate in a clinical trial aimed at decoding the human “immunome,” the genetic underpinnings of the immune system.
Potent HIV antibodies suggest new vaccine development approach
Apr. 7, 2016—It’s been known for some time that the immune system can produce antibodies capable of “neutralizing” HIV, and stopping the AIDS-causing virus dead in its tracks.
Vanderbilt researchers identify potential antibody treatment for H7 avian flu
Mar. 7, 2016—Researchers at Vanderbilt University Medical Center have isolated human antibodies against a type of bird flu that has killed more than 200 people in China since 2012 and which may pose a worldwide pandemic threat.
